 DMAC is a microcap biotech that has the first potential breakthrough stroke drug in 25 years, which addresses a 3.5 billion U.S. market. They initiated a phase 23 pivotal trial. Their drug, DM199, is the first synthetic version of a naturally occurring protein, KLK1. Porcine and human-derived KLK1 have been used for 20 years in Asia to treat strokekidney disease. 